SG10201801200PA - An h3 receptor antagonist for use in the treatment of alzheimer's disease - Google Patents
An h3 receptor antagonist for use in the treatment of alzheimer's diseaseInfo
- Publication number
- SG10201801200PA SG10201801200PA SG10201801200PA SG10201801200PA SG10201801200PA SG 10201801200P A SG10201801200P A SG 10201801200PA SG 10201801200P A SG10201801200P A SG 10201801200PA SG 10201801200P A SG10201801200P A SG 10201801200PA SG 10201801200P A SG10201801200P A SG 10201801200PA
- Authority
- SG
- Singapore
- Prior art keywords
- alzheimer
- disease
- treatment
- receptor antagonist
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305415.7A EP2647377A1 (en) | 2012-04-06 | 2012-04-06 | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| US201361792635P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201801200PA true SG10201801200PA (en) | 2018-04-27 |
Family
ID=46001073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801200PA SG10201801200PA (en) | 2012-04-06 | 2013-04-05 | An h3 receptor antagonist for use in the treatment of alzheimer's disease |
| SG11201406093VA SG11201406093VA (en) | 2012-04-06 | 2013-04-05 | An h3 receptor antagonist for use in the treatment of alzheimer's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406093VA SG11201406093VA (en) | 2012-04-06 | 2013-04-05 | An h3 receptor antagonist for use in the treatment of alzheimer's disease |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150031893A1 (pt) |
| EP (2) | EP2647377A1 (pt) |
| JP (1) | JP6143842B2 (pt) |
| KR (1) | KR20150000490A (pt) |
| CN (1) | CN104363911A (pt) |
| AR (1) | AR090605A1 (pt) |
| AU (1) | AU2013244928B2 (pt) |
| BR (1) | BR112014024736A2 (pt) |
| CA (1) | CA2868481A1 (pt) |
| ES (1) | ES2618924T3 (pt) |
| MX (1) | MX354020B (pt) |
| PL (1) | PL2833887T3 (pt) |
| RU (1) | RU2014144615A (pt) |
| SG (2) | SG10201801200PA (pt) |
| TW (1) | TW201402119A (pt) |
| UY (1) | UY34734A (pt) |
| WO (1) | WO2013150150A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| SG11201601306QA (en) * | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
| CN114053289B (zh) * | 2020-08-06 | 2023-06-27 | 北京箭牧科技有限公司 | 瑞德西韦在制备预防和治疗神经系统退行性疾病药物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| EP1554260A1 (en) | 2002-10-22 | 2005-07-20 | Glaxo Group Limited | Aryloxyalkylamine derivatives as h3 receptor ligands |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| MXPA05006567A (es) | 2002-12-20 | 2005-08-16 | Glaxo Group Ltd | Derivados de benzazepina para el tratamiento de trastornos neurologicos. |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20060293298A1 (en) | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
| AR044045A1 (es) | 2003-04-23 | 2005-08-24 | Glaxo Group Ltd | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion |
| WO2005014571A1 (en) | 2003-07-18 | 2005-02-17 | Glaxo Group Limited | Substituted piperidines as histamine h3 receptor ligands |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| AU2005250077B2 (en) | 2004-03-01 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| GB0408083D0 (en) | 2004-04-08 | 2004-05-12 | Glaxo Group Ltd | Novel compounds |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| EP1756094A1 (en) | 2004-06-18 | 2007-02-28 | Glaxo Group Limited | 3-cycloalkylbenzazepines as histamine h3 antagonists |
| GB0418267D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Novel compounds |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| PT1802307E (pt) | 2004-10-15 | 2008-06-06 | Glaxo Group Ltd | Derivados de pirrolidina como ligandos de receptores de histamina |
| US20090306052A1 (en) | 2004-12-07 | 2009-12-10 | Glaxo Group Limited | Indenyl derivatives and use thereof for the treatment of neurological disorders |
| JP2008533117A (ja) | 2005-03-14 | 2008-08-21 | グラクソ グループ リミテッド | ヒスタミンｈ３受容体に対して親和性を有する縮合チアゾール誘導体 |
| GB0513886D0 (en) | 2005-07-06 | 2005-08-10 | Glaxo Group Ltd | Novel compounds |
| EP1790646A1 (fr) | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
| MX2008015996A (es) | 2006-06-23 | 2009-01-20 | Esteve Labor Dr | Combinacion de un inhibidor de la colinesterasa y un compuesto con afinidad por el receptor 5-ht6. |
| CL2008000597A1 (es) | 2007-03-01 | 2008-09-05 | Glaxo Group Ltd | Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas. |
| PE20091199A1 (es) | 2007-09-06 | 2009-09-12 | Glaxo Group Ltd | Derivado de piperazina que tiene afinidad por el receptor de histamina h3 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP2012500823A (ja) | 2008-08-29 | 2012-01-12 | グラクソ グループ リミテッド | １−イソプロピル−４−｛［４−（テトラヒドロ−２ｈ−ピラン−４−イルオキシ）フェニル］カルボニル｝ヘキサヒドロ−１ｈ−１，４−ジアゼピンまたはその塩を含んでなる剤形 |
| WO2010026113A1 (en) * | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| PL2445899T3 (pl) | 2009-06-26 | 2017-08-31 | Sanofi | Nowe sole fumaranowe antagonisty receptora histaminy H3 |
| TW201118099A (en) | 2009-08-12 | 2011-06-01 | Boehringer Ingelheim Int | New compounds for the treatment of CNS disorders |
| WO2011051423A1 (en) | 2009-11-02 | 2011-05-05 | Glaxo Group Limited | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
| FR2976286B1 (fr) | 2011-06-08 | 2013-05-24 | Servier Lab | 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
| SG11201601306QA (en) * | 2013-09-09 | 2016-03-30 | Sanofi Sa | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease |
-
2012
- 2012-04-06 EP EP12305415.7A patent/EP2647377A1/en not_active Ceased
-
2013
- 2013-04-03 TW TW102112006A patent/TW201402119A/zh unknown
- 2013-04-04 AR ARP130101105A patent/AR090605A1/es unknown
- 2013-04-05 SG SG10201801200PA patent/SG10201801200PA/en unknown
- 2013-04-05 CN CN201380029300.6A patent/CN104363911A/zh active Pending
- 2013-04-05 AU AU2013244928A patent/AU2013244928B2/en not_active Ceased
- 2013-04-05 MX MX2014011992A patent/MX354020B/es active IP Right Grant
- 2013-04-05 KR KR1020147029735A patent/KR20150000490A/ko not_active Application Discontinuation
- 2013-04-05 ES ES13714652.8T patent/ES2618924T3/es active Active
- 2013-04-05 WO PCT/EP2013/057241 patent/WO2013150150A1/en active Application Filing
- 2013-04-05 RU RU2014144615A patent/RU2014144615A/ru unknown
- 2013-04-05 JP JP2015503896A patent/JP6143842B2/ja not_active Expired - Fee Related
- 2013-04-05 CA CA2868481A patent/CA2868481A1/en not_active Abandoned
- 2013-04-05 PL PL13714652T patent/PL2833887T3/pl unknown
- 2013-04-05 EP EP13714652.8A patent/EP2833887B1/en not_active Not-in-force
- 2013-04-05 SG SG11201406093VA patent/SG11201406093VA/en unknown
- 2013-04-05 BR BR112014024736A patent/BR112014024736A2/pt not_active IP Right Cessation
- 2013-04-05 UY UY0001034734A patent/UY34734A/es not_active Application Discontinuation
-
2014
- 2014-10-03 US US14/506,089 patent/US20150031893A1/en not_active Abandoned
-
2015
- 2015-10-01 US US14/872,812 patent/US9789102B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013244928B2 (en) | 2017-08-10 |
| JP6143842B2 (ja) | 2017-06-07 |
| MX354020B (es) | 2018-02-08 |
| PL2833887T3 (pl) | 2017-06-30 |
| US20160101099A1 (en) | 2016-04-14 |
| UY34734A (es) | 2013-11-29 |
| EP2833887A1 (en) | 2015-02-11 |
| EP2833887B1 (en) | 2016-12-28 |
| EP2647377A1 (en) | 2013-10-09 |
| RU2014144615A (ru) | 2016-05-27 |
| BR112014024736A2 (pt) | 2017-07-11 |
| CA2868481A1 (en) | 2013-10-10 |
| CN104363911A (zh) | 2015-02-18 |
| WO2013150150A1 (en) | 2013-10-10 |
| TW201402119A (zh) | 2014-01-16 |
| ES2618924T3 (es) | 2017-06-22 |
| MX2014011992A (es) | 2015-05-08 |
| AU2013244928A1 (en) | 2014-10-30 |
| SG11201406093VA (en) | 2014-10-30 |
| KR20150000490A (ko) | 2015-01-02 |
| US9789102B2 (en) | 2017-10-17 |
| AR090605A1 (es) | 2014-11-26 |
| US20150031893A1 (en) | 2015-01-29 |
| JP2015516963A (ja) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
| IL269511A (en) | New therapeutic approaches to treat Parkinson's disease | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| EP2911664A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| RS64744B1 (sr) | Jedinjenja za upotrebu u lečenju alchajmerove bolesti kod pacijenata sa apoe4+/+ | |
| SG11201601306QA (en) | An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| EP2978446A4 (en) | METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| IL230441A0 (en) | Diagnosis of Alzheimer's disease | |
| IL233572A0 (en) | A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease | |
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| EP2906225A4 (en) | METHODS OF TREATING KENNEDY'S DISEASE | |
| EP2829605A4 (en) | PROCESS FOR SCREENING THERAPEUTIC AND / OR PROPHYLACTICS FOR MORBUS ALZHEIMER | |
| EP2667896A4 (en) | METHOD AND COMPOSITION FOR TREATING MORBUS ALZHEIMER | |
| SG11201406093VA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| IL234412B (en) | The iloperidone metabolite for use in the treatment of psychiatric diseases | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| FR2989088B1 (fr) | Radiotraceur pour la maladie d'alzheimer |